tility of 3-dimensional gait analysis in reference to clinical assessments to detect significant change after a cerebrospinal fluid tap test in patients investigated for idiopathic normal pressure hydrocephalus

Salford Royal NHS Foundation Trust0 sites20 target enrollmentDecember 8, 2022

Overview

No summary available.

Registry

who.int

Start Date

December 8, 2022

End Date

June 30, 2025

Last Updated

last year

Study Type

Interventional

Sex

All

Sponsor

Salford Royal NHS Foundation Trust

•1\. Consenting males and females diagnosed with iNPH according to the international guidelines for diagnosing iNPH. Patients younger than age 60 may be included on a case by case basis.
•2\. Should be able to walk unaided for at least 20 steps at a time; walking aids will be permitted to reflect the reality of this condition for many patients.
•3\. Consenting healthy volunteers, of similar age and sex distribution, without iNPH. Chronic stable health conditions and chronic stable medications (e.g. hypertension on long term antihypertensive medication) with no substantive impact on performance and participation in this study as judged by the investigators are permitted.

•1\. Other confirmed medical or surgical conditions better explaining symptoms than iNPH (patients) or with substantive impact (eg Parkinson’s, osteoarthritis) as judged by the investigators (patients and control)
•2\. Secondary or obstructive hydrocephalus; previous surgical procedures for hydrocephalus (patients)
•3\. Amputation of lower limb/appendages
•4\. Musculoskeletal injury/recent lower\-limb surgeries affecting gait or other musculoskeletal ailments affecting gait and balance performance as judged by the investigators
•5\. Participants on specific medications (eg centrally acting) better explaining symptoms than iNPH (patients) or with substantive impact as judged by the investigators (patients and control)
•6\. Unable to carry out all study procedures
•7\. Unable to comprehend informed consent